Active, not recruitingNCT03060720
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
Studying Familial pancreatic carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Matthew B Yurgelun, MDDana-Farber Cancer Institute
- Enrollment
- 271 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2028
Study locations (1)
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03060720 on ClinicalTrials.govOther trials for Familial pancreatic carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07344220Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye ConjugateHoag Memorial Hospital Presbyterian
- ENROLLING BY INVITATIONNANCT06744595Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic CancerMayo Clinic
- RECRUITINGNCT04743479Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)Changhai Hospital
- ACTIVE NOT RECRUITINGNCT04247503Cohort Study of Pancreatic Cancer RiskMayo Clinic
- RECRUITINGNCT01102569Pancreatic Cancer GeneticsColumbia University
- ACTIVE NOT RECRUITINGNCT00835133Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and MelanomaMayo Clinic